866-997-4948(US-Canada Toll Free)

Smallpox - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Mar 2014

Category :

Diseases & Conditions

No. of Pages : 92 Pages

Smallpox - Pipeline Review, H1 2014


Global Markets Directs, Smallpox - Pipeline Review, H1 2014, provides an overview of the Smallpoxs therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Smallpox
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Smallpox and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Smallpox products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Smallpox pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Smallpox
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Smallpox pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
ort Coverage 7
Smallpox Overview 8
Therapeutics Development 9
Pipeline Products for Smallpox Overview 9
Pipeline Products for Smallpox Comparative Analysis 10
Smallpox Therapeutics under Development by Companies 11
Smallpox Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Smallpox Products under Development by Companies 17
Smallpox Companies Involved in Therapeutics Development 18
Inovio Pharmaceuticals, Inc. 18
Bavarian Nordic A/S 19
Symphogen A/S 20
Nanotherapeutics, Inc. 21
CEL-SCI Corporation 22
GeoVax Labs, Inc. 23
SIGA Technologies, Inc. 24
TapImmune Inc. 25
CJ CheilJedang Corp. 26
MacroGenics, Inc. 27
AlphaVax, Inc. 28
EpiVax, Inc. 29
Chimerix, Inc. 30
NanoBio Corporation 31
Conkwest, Inc. 32
Smallpox Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 43
live modified vaccinia virus ankara - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
CJ-50300 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
brincidofovir - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
tecovirimat - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
tecovirimat - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Sym-002 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
cidofovir - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
CEL-1000 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
tecovirimat - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
DNA Vaccine For Smallpox - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Smallpox Vaccine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
CST-102 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Smallpox Vaccine - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Modified Vaccinia Ankara Transporters Associated with Antigen Processing - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
MVA Vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
SmallPox Vaccine - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
IkT-001 Pro - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Mult. mAbs/DARTs - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
PL-801 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
tecovirimat - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Smallpox Recent Pipeline Updates 72
Smallpox Dormant Projects 82
Smallpox Product Development Milestones 83
Featured News & Press Releases 83
Nov 22, 2013: Bavarian Nordic Receives Health Canada Approval of IMVAMUNE Smallpox Vaccine 83
Nov 15, 2013: Bavarian Nordic Completes Delivery of 20 Million Doses of IMVAMUNE Smallpox Vaccine to the U.S. Strategic National Stockpile 83
Aug 07, 2013: Bavarian Nordic Receives European Marketing Authorization for IMVANEX Smallpox Vaccine 84
Jun 03, 2013: Chimerix And BARDA Continue Collaboration On Development Of CMX001 As Medical Countermeasure Against Smallpox 85
May 31, 2013: Bavarian Nordic's Imvanex Vaccine Receives Positive CHMP Opinion For Active Immunization Against Smallpox 86
May 29, 2013: SIGA Completes Second Delivery Of Arestvyr Under BARDA Contract 87
May 26, 2013: PharmAthene Announces Delaware Supreme Court Upholds Lower Court Ruling In Lawsuit Against SIGA Technologies 87
May 16, 2013: Chimerix Presents Data On CMX001 At 26th International Conference On Antiviral Research 87
Apr 16, 2013: Bavarian Nordic Receives Contract Valued Up To $228m From BARDA Securing Continued Production And Deliveries Of Imvamune Smallpox Vaccine 89
Mar 12, 2013: Siga Delivers First Courses Of Arestvyr To US Strategic National Stockpile Under BARDA Contract 90
Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 92
Disclaimer 92

List of Table

List of Tables
Number of Products under Development for Smallpox, H1 2014 9
Number of Products under Development for Smallpox Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Comparative Analysis by Unknown Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Smallpox Pipeline by Inovio Pharmaceuticals, Inc., H1 2014 18
Smallpox Pipeline by Bavarian Nordic A/S, H1 2014 19
Smallpox Pipeline by Symphogen A/S, H1 2014 20
Smallpox Pipeline by Nanotherapeutics, Inc., H1 2014 21
Smallpox Pipeline by CEL-SCI Corporation, H1 2014 22
Smallpox Pipeline by GeoVax Labs, Inc., H1 2014 23
Smallpox Pipeline by SIGA Technologies, Inc., H1 2014 24
Smallpox Pipeline by TapImmune Inc., H1 2014 25
Smallpox Pipeline by CJ CheilJedang Corp., H1 2014 26
Smallpox Pipeline by MacroGenics, Inc., H1 2014 27
Smallpox Pipeline by AlphaVax, Inc., H1 2014 28
Smallpox Pipeline by EpiVax, Inc., H1 2014 29
Smallpox Pipeline by Chimerix, Inc., H1 2014 30
Smallpox Pipeline by NanoBio Corporation, H1 2014 31
Smallpox Pipeline by Conkwest, Inc., H1 2014 32
Assessment by Monotherapy Products, H1 2014 33
Number of Products by Stage and Target, H1 2014 35
Number of Products by Stage and Mechanism of Action, H1 2014 37
Number of Products by Stage and Route of Administration, H1 2014 39
Number of Products by Stage and Molecule Type, H1 2014 42
Smallpox Therapeutics Recent Pipeline Updates, H1 2014 72
Smallpox Dormant Projects, H1 2014 82

List of Chart

List of Figures
Number of Products under Development for Smallpox, H1 2014 9
Number of Products under Development for Smallpox Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Early Stage Products, H1 2014 15
Assessment by Monotherapy Products, H1 2014 33
Number of Products by Top 10 Target, H1 2014 34
Number of Products by Stage and Top 10 Target, H1 2014 35
Number of Products by Top 10 Mechanism of Action, H1 2014 36
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 37
Number of Products by Top 10 Route of Administration, H1 2014 38
Number of Products by Stage and Top 10 Route of Administration, H1 2014 39
Number of Products by Top 10 Molecule Type, H1 2014 40
Number of Products by Stage and Top 10 Molecule Type, H1 2014 41

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *